AstraZeneca Back In The PARP Mix With Olaparib In Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Olaparib is off the shelf and into a Phase III trial against ovarian cancer in platinum-sensitive BRCA-positive patients, adding to the list of late-stage PARP inhibitors vying for first-in-class status.
You may also be interested in...
Myriad Wields Proprietary Database To Protect Testing Market
Myriad president Mark Capone made it clear that the company will use its proprietary database of genetic variants on the BRCA1 and BRCA2 genes to try and fend off cheaper competition after the BRACAnalysis test’s method patents are expired, or if they are overturned in court.
Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Pharma Adapts Ovarian Cancer Drugs Amid Genomics Revolution
Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.